What is NewGenIvf Group's earnings per share (EPS)?

NewGenIvf Group (NIVF) reported diluted earnings per share of $3.04 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NewGenIvf Group Financials

NIVF

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows NewGenIvf Group (NIVF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NIVF FY2025 2026-04-22

External financing is masking a core cash-burning operation whose reported FY2025 profit did not come from day-to-day business.

By FY2025, net income turned positive at $9.9M, yet operating cash flow was -$10.9M. With operating margin at -226.9% and the prior two years not showing this profit shape, reported earnings appear to have been driven by non-operating items rather than a recovery in the underlying business.

After two years near 33%, gross margin fell to 20.2% in FY2025. At the same time, selling and administrative cost reached $10.5M, far above gross profit of $956K, so the operating problem is both weaker unit economics and an overhead load that now dwarfs the revenue base.

The balance sheet swung back to positive equity of $26.6M in FY2025, but that repair came alongside $19.0M of financing inflow. Liquidity therefore improved because outside capital arrived, while cash on hand of $759K remained tiny beside free cash outflow of -$11.1M.

Financial Health Signals

Financial Profile 43/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of NewGenIvf Group's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

NewGenIvf Group has an operating margin of -226.9%, meaning the company retains $-227 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -21.4% the prior year.

Growth

NewGenIvf Group's revenue declined 13% year-over-year, from $5.4M to $4.7M. This contraction results in a growth score of 27/100.

Leverage

NewGenIvf Group carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

NewGenIvf Group's current ratio of 3.12 indicates adequate short-term liquidity, earning a score of 60/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While NewGenIvf Group generated -$10.9M in operating cash flow, capex of $135K consumed most of it, leaving -$11.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

NewGenIvf Group earns a strong 37.1% return on equity (ROE), meaning it generates $37 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 72/100.

Piotroski F-Score Weak

3/9

NewGenIvf Group passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

-1.11x

For every $1 of reported earnings, NewGenIvf Group generates $-1.11 in operating cash flow (-$10.9M OCF vs $9.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-17.4x

NewGenIvf Group earns $-17.4 in operating income for every $1 of interest expense (-$10.7M vs $616K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.7M

YoY-13.0%

NewGenIvf Group generated $4.7M in revenue in fiscal year 2025. This represents a decrease of 13.0% from the prior year.

EBITDA

-$10.5M

YoY-823.6%

NewGenIvf Group's EBITDA was -$10.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 823.6% from the prior year.

Net Income

$9.9M

YoY+1983.1%

NewGenIvf Group reported $9.9M in net income in fiscal year 2025. This represents an increase of 1983.1% from the prior year.

EPS (Diluted)

$3.04

NewGenIvf Group earned $3.04 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$11.1M

YoY-33.0%

NewGenIvf Group generated -$11.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 33.0% from the prior year.

Cash & Debt

$759K

YoY+65.7%

NewGenIvf Group held $759K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

240,622

NewGenIvf Group had 240,622 shares outstanding in fiscal year 2025. This represents an increase of 63221.6% from the prior year.

Margins & Returns

Gross Margin

20.2%

YoY-13.4pp

NewGenIvf Group's gross margin was 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 13.4 percentage points from the prior year.

Operating Margin

-226.9%

YoY-205.6pp

NewGenIvf Group's operating margin was -226.9% in fiscal year 2025, reflecting core business profitability. This is down 205.6 percentage points from the prior year.

Net Margin

209.0%

YoY+218.7pp

NewGenIvf Group's net profit margin was 209.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 218.7 percentage points from the prior year.

Return on Equity

37.1%

NewGenIvf Group's ROE was 37.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$135K

YoY+154.5%

NewGenIvf Group invested $135K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 154.5% from the prior year.

NIVF Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	$4.7M-13.0%	$5.4M+5.8%	$5.1M-13.6%	$5.9M+44.3%	$4.1M
Cost of Revenue	$3.8M+4.6%	$3.6M+4.4%	$3.5M-21.6%	$4.4M+42.4%	$3.1M
Gross Profit	$956K-47.7%	$1.8M+8.6%	$1.7M+9.4%	$1.5M+50.1%	$1.0M
R&D Expenses	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$10.5M+277.3%	$2.8M+71.5%	$1.6M+47.0%	$1.1M+37.6%	$801K
Operating Income	-$10.7M-824.3%	-$1.2M-2847.3%	$42K-89.4%	$399K+100.6%	$199K
Interest Expense	$616K-19.4%	$765K+1557.0%	$46K	N/A	N/A
Income Tax	N/A	-$487K	N/A	$208K-29.4%	$295K
Net Income	$9.9M+1983.1%	-$525K-503.0%	$130K-71.6%	$459K+86153.8%	-$533
EPS (Diluted)	$3.04	$-4408.76	$13019.30+275732.6%	$4.72	$0.00

Metric	Q4'25	Q4'24	Q4'23	Q4'22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A

NIVF Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$32.7M+814.6%	$3.6M-20.3%	$4.5M+54.5%	$2.9M	N/A
Current Assets	$7.4M+132.7%	$3.2M+29.0%	$2.5M+2.5%	$2.4M	N/A
Cash & Equivalents	$759K+65.7%	$458K+746.0%	$54K+96.3%	$28K-4.2%	$29K
Inventory	$335K+315.0%	$81K-36.0%	$126K+169.2%	$47K	N/A
Accounts Receivable	$167K+238.2%	$49K+425.3%	$9K-27.9%	$13K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.7M+33.1%	$5.1M+307.6%	$1.2M-55.7%	$2.8M	N/A
Current Liabilities	$2.4M-13.0%	$2.7M+142.4%	$1.1M-56.1%	$2.6M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$26.6M+2639.7%	-$1.0M-128.1%	$3.7M+563.4%	$563K+161.5%	-$915K
Retained Earnings	$8.9M+1002.0%	-$986K-113.7%	-$461K+22.0%	-$592K	N/A

Metric	Q4'25	Q4'24	Q4'23	Q4'22
Total Assets	$32.7M+814.6%	$3.6M-20.3%	$4.5M+54.5%	$2.9M
Current Assets	$7.4M+132.7%	$3.2M+29.0%	$2.5M+2.5%	$2.4M
Cash & Equivalents	$759K+65.7%	$458K+746.0%	$54K+96.3%	$28K
Inventory	$335K+315.0%	$81K-36.0%	$126K+169.2%	$47K
Accounts Receivable	$167K+238.2%	$49K+425.3%	$9K-27.9%	$13K
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$6.7M+33.1%	$5.1M+307.6%	$1.2M-55.7%	$2.8M
Current Liabilities	$2.4M-13.0%	$2.7M+142.4%	$1.1M-56.1%	$2.6M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$26.6M+2639.7%	-$1.0M-128.1%	$3.7M+563.4%	$563K
Retained Earnings	$8.9M+1002.0%	-$986K-113.7%	-$461K+22.0%	-$592K

NIVF Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$10.9M-32.2%	-$8.3M-367.9%	-$1.8M-203.2%	$1.7M+19.4%	$1.4M
Capital Expenditures	$135K+154.5%	$53K-24.1%	$70K-26.0%	$94K+469.8%	$17K
Free Cash Flow	-$11.1M-33.0%	-$8.3M-353.0%	-$1.8M-213.6%	$1.6M+14.1%	$1.4M
Investing Cash Flow	-$7.6M-14151.6%	-$53K+24.1%	-$70K+26.0%	-$94K-469.8%	-$17K
Financing Cash Flow	$19.0M+118.9%	$8.7M+361.1%	$1.9M+215.2%	-$1.6M-5.8%	-$1.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q4'24	Q4'23	Q4'22
Operating Cash Flow	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

NIVF Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	20.2%-13.4pp	33.6%+0.9pp	32.7%+6.9pp	25.9%+1.0pp	24.9%
Operating Margin	-226.9%-205.6pp	-21.4%-22.2pp	0.8%-5.9pp	6.7%+1.9pp	4.8%
Net Margin	209.0%+218.7pp	-9.7%-12.2pp	2.5%-5.2pp	7.7%+7.7pp	-0.0%
Return on Equity	37.1%	N/A	3.5%-78.0pp	81.5%	N/A
Return on Assets	30.2%+44.9pp	-14.7%-17.6pp	2.9%-12.9pp	15.8%	N/A
Current Ratio	3.12+2.0	1.17-1.0	2.19+1.3	0.94	N/A
Debt-to-Equity	0.25+5.1	-4.82-5.2	0.33-4.6	4.98	N/A
FCF Margin	-234.0%-81.0pp	-153.1%-117.3pp	-35.8%-62.9pp	27.2%-7.2pp	34.4%

Metric	Q4'25	Q4'24	Q4'23	Q4'22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A
Current Ratio	3.12+2.0	1.17-1.0	2.19+1.3	0.94
Debt-to-Equity	0.25+5.1	-4.82-5.2	0.33-4.6	4.98
FCF Margin	N/A	N/A	N/A	N/A

Similar Companies

Modivcare Inc MODV

$6.2M

Concord Medical CCM

$17.0M

Amer Shared Hosp AMS

$9.0M

Cryo-Cell Intl Inc CCEL

$28.7M

Basel Medical Group Ltd BMGL

$11.6M

Frequently Asked Questions

What is NewGenIvf Group's annual revenue?

NewGenIvf Group (NIVF) reported $4.7M in total revenue for fiscal year 2025. This represents a -13.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is NewGenIvf Group's revenue growing?

NewGenIvf Group (NIVF) revenue declined by 13% year-over-year, from $5.4M to $4.7M in fiscal year 2025.

Is NewGenIvf Group profitable?

Yes, NewGenIvf Group (NIVF) reported a net income of $9.9M in fiscal year 2025, with a net profit margin of 209.0%.

What is NewGenIvf Group's EBITDA?

NewGenIvf Group (NIVF) had EBITDA of -$10.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is NewGenIvf Group's gross margin?

NewGenIvf Group (NIVF) had a gross margin of 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is NewGenIvf Group's operating margin?

NewGenIvf Group (NIVF) had an operating margin of -226.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is NewGenIvf Group's net profit margin?

NewGenIvf Group (NIVF) had a net profit margin of 209.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is NewGenIvf Group's return on equity (ROE)?

NewGenIvf Group (NIVF) has a return on equity of 37.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is NewGenIvf Group's free cash flow?

NewGenIvf Group (NIVF) generated -$11.1M in free cash flow during fiscal year 2025. This represents a -33.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is NewGenIvf Group's operating cash flow?

NewGenIvf Group (NIVF) generated -$10.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are NewGenIvf Group's total assets?

NewGenIvf Group (NIVF) had $32.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are NewGenIvf Group's capital expenditures?

NewGenIvf Group (NIVF) invested $135K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does NewGenIvf Group have outstanding?

NewGenIvf Group (NIVF) had 240,622 shares outstanding as of fiscal year 2025.

What is NewGenIvf Group's current ratio?

NewGenIvf Group (NIVF) had a current ratio of 3.12 as of fiscal year 2025, which is generally considered healthy.

What is NewGenIvf Group's debt-to-equity ratio?

NewGenIvf Group (NIVF) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is NewGenIvf Group's return on assets (ROA)?

NewGenIvf Group (NIVF) had a return on assets of 30.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is NewGenIvf Group's cash runway?

Based on fiscal year 2025 data, NewGenIvf Group (NIVF) had $759K in cash against an annual operating cash burn of $10.9M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is NewGenIvf Group's Piotroski F-Score?

NewGenIvf Group (NIVF) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NewGenIvf Group's earnings high quality?

NewGenIvf Group (NIVF) has an earnings quality ratio of -1.11x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can NewGenIvf Group cover its interest payments?

NewGenIvf Group (NIVF) has an interest coverage ratio of -17.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is NewGenIvf Group?

NewGenIvf Group (NIVF) scores 43 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.